- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00162123
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
28. Juni 2016 aktualisiert von: Bristol-Myers Squibb
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment.
In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintenance or reinduction therapy.
Studienübersicht
Studientyp
Interventionell
Einschreibung (Tatsächlich)
248
Phase
- Phase 2
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Buenos Aires, Argentinien, CP1280AEB
- Local Institution
-
-
-
-
-
Brussels, Belgien, 1090
- Local Institution
-
Brussels, Belgien, 1070
- Local Institution
-
Bruxelles, Belgien, 1200
- Local Institution
-
-
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brasilien, 90610
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, Brasilien, 90050
- Local Institution
-
-
Sao Paulo
-
Jau, Sao Paulo, Brasilien, 17210
- Local Institution
-
-
-
-
-
Berlin, Deutschland, D-12200
- Local Institution
-
Heidelberg, Deutschland, 69120
- Local Institution
-
Kiel, Deutschland, D-24105
- Local Institution
-
-
-
-
-
Aarhus C, Dänemark, 8000
- Local Institution
-
-
-
-
-
Brest, Frankreich, 29200
- Local Institution
-
Lyon Cedex 08, Frankreich, 69373
- Local Institution
-
Paris, Frankreich, 75010
- Local Institution
-
Vandoeuvre Les Nancy, Frankreich, 54511
- Local Institution
-
-
-
-
-
Jerusalem, Israel, 91120
- Local Institution
-
Tel-Aviv, Israel, 64239
- Local Institution
-
-
-
-
-
Genova, Italien, 16132
- Local Institution
-
Meldola (Fc), Italien, 47014
- Local Institution
-
Rimini, Italien, 47900
- Local Institution
-
Siena, Italien, 53100
- Local Institution
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 4N2
- Local Institution
-
Edmonton, Alberta, Kanada, T6G 1Z2
- Local Institution
-
-
New Brunswick
-
Moncton, New Brunswick, Kanada, E1C 6Z8
- Local Institution
-
-
-
-
-
Oslo, Norwegen, 0310
- Local Institution
-
-
-
-
-
Lodz, Polen, 90553
- Local Institution
-
Poznan, Polen, 61-866
- Local Institution
-
Wroclaw, Polen, 51-124
- Local Institution
-
-
-
-
-
St. Petersburg, Russische Föderation, 191104
- Local Institution
-
Stavropol, Russische Föderation, 355047
- Local Institution
-
Voronezh, Russische Föderation, 394000
- Local Institution
-
-
-
-
-
Malaga, Spanien, 29010
- Local Institution
-
Valencia, Spanien, 46009
- Local Institution
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, Südafrika, 2199
- Local Institution
-
-
Western Cape
-
Cape Town, Western Cape, Südafrika, 7570
- Local Institution
-
-
-
-
-
Olomouc, Tschechische Republik, 775 20
- Local Institution
-
-
-
-
-
Dnepropetrovsk, Ukraine, 49044
- Local Institution
-
-
-
-
Arizona
-
Tucson, Arizona, Vereinigte Staaten, 85719
- University of Arizona Cancer Center
-
-
California
-
Laverne, California, Vereinigte Staaten, 91750
- Wilshire Oncology Medical Group Inc
-
Los Angeles, California, Vereinigte Staaten, 90033
- USC/Norris Comprehensive Cancer Center
-
Los Angeles, California, Vereinigte Staaten, 90025
- The Angeles Clinic & Research Inst.
-
San Francisco, California, Vereinigte Staaten, 94115
- San Francisco Oncology Associates
-
-
Connecticut
-
To come, Connecticut, Vereinigte Staaten
- Local Institution
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32207
- Baptist Cancer Institute
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- University of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Indiana Oncology Hematology Consultants
-
-
Missouri
-
Saint Louis, Missouri, Vereinigte Staaten, 63110
- Washington University School of Medicine
-
St Joseph, Missouri, Vereinigte Staaten, 64507
- St Joseph Oncology Inc
-
-
New York
-
New York, New York, Vereinigte Staaten, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28203
- Carolinas Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45219
- The Christ Hospital Cancer Center Research
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97213
- Providence Portland Medical Center
-
-
South Carolina
-
Greenville, South Carolina, Vereinigte Staaten, 29615
- Cancer Centers of the Carolinas
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75230
- Center For Oncology Research & Treatment, P.A.
-
Lubbock, Texas, Vereinigte Staaten, 79410
- Joe Arrington Cancer Research and Treatment Center
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98109
- University of Washington Medical Center
-
-
-
-
-
Wels, Österreich, A-4600
- Local Institution
-
Wien, Österreich, 1090
- Local Institution
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Key Inclusion Criteria
- Diagnosis of advanced melanoma
- Prior treatment in a prespecified prior/parent ipilimumab study
- Men and women 18 years of age and older
First Reinduction:
- No unacceptable toxicity (except select reversible immune-related adverse events) requiring ipilimumab discontinuation
- Had experienced documented progressive disease after expanded clinical benefit
Extended Maintenance
- Received ipilimumab at any dose in a parent study
- Achieved expanded clinical benefit at the time of entry to current study
Follow-up:
- Received ipilimumab at any dose in a closing parent study
- Deemed ineligible for reinduction or extended maintenance treatment or refused treatment as reinduction or extended maintenance at the time of screening in the current study, but consented to follow-up
Key Exclusion Criteria
- Prior treatment with a CD137 agonist or a cytotoxic T-lymphocyte antigen 4 inhibitor or agonist, other than ipilimumab
- Primary ocular or mucosal melanoma
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: First reinduction: Ipilimumab, 0.3 to 10 mg/kg
Participants who initially received ipilimumab, 0.3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Andere Namen:
|
|
Experimental: First reinduction: Ipilimumab, 3 to 10 mg/kg
Participants who initially received ipilimumab, 3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Andere Namen:
|
|
Experimental: First reinduction: Ipilimumab, 10 to 10 mg/kg
Participants who initially received ipilimumab, 10 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Andere Namen:
|
|
Experimental: Extended maintenance: Ipilimumab, 0.3 mg/kg
Participants who received ipilimumab, 0.3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (0.3 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Andere Namen:
|
|
Experimental: Extended maintenance: Ipilimumab, 3 mg/kg
Participants who received ipilimumab, 3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (3 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Andere Namen:
|
|
Experimental: Extended maintenance: Ipilimumab, 10 mg
Participants who received ipilimumab, 10 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (10 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Andere Namen:
|
|
Kein Eingriff: Follow-up
Participants did not receive any additional study treatment in current study but continued follow-up for the collection of survival data.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Participants With On-study Adverse Events (AEs), AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Drug-related AEs, Immune-related AEs (irAEs), and Death as Outcome
Zeitfenster: Continuously from first dose to 70 days after last dose of study drug. For deaths, Day 1 of enrollment to 70 days after last dose of study drug.
|
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
An SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Drug-related is defined as having certain, probable, possible, or missing relationship to study drug.
An IrAE is an AE characterized by a potential association with inflammation and considered by the investigator to be drug related.
Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.
|
Continuously from first dose to 70 days after last dose of study drug. For deaths, Day 1 of enrollment to 70 days after last dose of study drug.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall Survival (OS)
Zeitfenster: From first dose of study drug in parent study to death or date of last censoring.
|
OS was computed for all patients who entered this study and is defined as the time between the first dose of study therapy and death.
If a patient has not died, OS was censored at the time of last contact.
|
From first dose of study drug in parent study to death or date of last censoring.
|
|
Percentage of Participants Surviving at 1, 1.5, and 2 Years
Zeitfenster: From first dose of study drug in parent study to up to 2 years after reinduction
|
Survival rate was defined as the time from first dose of study drug to 1, 1.5, and 2 years.
|
From first dose of study drug in parent study to up to 2 years after reinduction
|
|
Number of Participants With On-study Immune-related Adverse Events (irAEs)
Zeitfenster: From first dose of study drug during reinduction to the earliest of 70 days after last dose or day before second reinduction first dose date
|
irAEs were defined as adverse events characterized by a potential association with inflammation and considered by the investigator as drug related.
These prespecified terms were grouped into the following organ-specific subcategories: gastrointestinal, hepatic, skin, endocrine, neurologic, and other (includes blood, eye, immune system, investigations, infections, renal, and respiratory systems).
Patients may have 1 or more events.
|
From first dose of study drug during reinduction to the earliest of 70 days after last dose or day before second reinduction first dose date
|
|
Progression-free Survival (PFS)
Zeitfenster: From day of first reinduction in current study to date of progression or death, whichever occurred first.
|
PFS was defined as the time between the date of the baseline tumor assessment in this study and the date of progression or death, whichever occurred first.
|
From day of first reinduction in current study to date of progression or death, whichever occurred first.
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Nützliche Links
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Mai 2006
Primärer Abschluss (Tatsächlich)
1. September 2012
Studienabschluss (Tatsächlich)
1. April 2014
Studienanmeldedaten
Zuerst eingereicht
9. September 2005
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
9. September 2005
Zuerst gepostet (Schätzen)
13. September 2005
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
27. Juli 2016
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
28. Juni 2016
Zuletzt verifiziert
1. Juni 2016
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach histologischem Typ
- Neubildungen
- Neuroektodermale Tumoren
- Neoplasmen, Keimzelle und Embryonal
- Neubildungen, Nervengewebe
- Neuroendokrine Tumoren
- Nävi und Melanome
- Melanom
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antineoplastische Mittel
- Antineoplastische Mittel, immunologische
- Immun-Checkpoint-Inhibitoren
- Ipilimumab
Andere Studien-ID-Nummern
- CA184-025
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .